Consistent Trial Site Payments Key to Long-Term Relationships with Investigators

By Zachary Brennan

- Last updated on GMT

Consistent Trial Site Payments Key to Better Relationships

Related tags: Clinical trial, Clinical research

The days of using Excel spreadsheets to manage clinical trial site payments are now in the past, especially as CROs and sponsors look to retain their most highly-prized sites and establish long-term relationships for future trials.

The top complaint from trial sites is the untimeliness and errors around payments, Steve Ayala, president and CFO of Clinverse, told us. He said that often times it can take between six and 18 months after a site finishes its work before the sponsor, CRO (clinical research organization) and site can reconcile what should be paid and before the site receives its payment.

Between 35% and 40% of the industry migrated away from an entirely manual system but to a mix between excel spreadsheets, a CTMS (clinical trial management system) and a variety of other tech tools to help make payments, Ayala said.

Clinverse, Greenphire, CFS Clinical and Payoneer all offer varying global payment systems that can help CROs and sponsors make more timely payments.

Barb Geiger, EVP of CRO Clinipace, and Mark Shapiro, executive director of clinical development at Clinipace, agreed that the Clinpay tool is innovative, but they also said that Greenphire has been in the business longer. Geiger added that on the list of priorities, site payments are on the lower end of what's crucial for upper-level management. 

Ayala said Clinverse is “pro-actively targeting​” small and mid-size CROs and sponsors, although a number of the top pharma and CROs are beginning to reach out because “we’re the only ones that can handle any term negotiated in a contract​.” He noted that implementation of the his company’s Clinpay system is akin to adopting an EDC (electronic data capture) system.

The Clinverse tool is also now being used by CROs and sponsors as a motivator to modify trial site behaviors, Ayala said. ​In one scenario, Clinpay can allowsites to receive a percentage of the negotiated contract payment when all case report forms required at a particular patient visit have been entered, while a portion of the funds can be held back and released when patient visits are monitored and query free, and the rest is paid at the end of the trial.

Sunshine Deadline Approaching

As the August 1 deadline quickly approaches for pharma companies to begin collecting provider payment data to submit to CMS (Centers for Medicaid and Medicare Service) in March 2014, CROs are beginning to feel the pressure of a law that they perhaps once thought would only tangentially impact them.

Ayala said CROs are beginning to feel pressure from the sponsors they work with to begin adopting tools that will help to compile the data. Many sponsors are also asking for information beyond what CMS is requesting for internal purposes, which is complicating what CROs will have to do to meet these terms of compliance, he added.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars